SEL + SIM
Phase 2Completed 1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Non-Alcoholic Steatohepatitis (NASH)
Conditions
Non-Alcoholic Steatohepatitis (NASH)
Trial Timeline
Jun 8, 2015 → Oct 11, 2016
NCT ID
NCT02466516About SEL + SIM
SEL + SIM is a phase 2 stage product being developed by Gilead Sciences for Non-Alcoholic Steatohepatitis (NASH). The current trial status is completed. This product is registered under clinical trial identifier NCT02466516. Target conditions include Non-Alcoholic Steatohepatitis (NASH).
What happened to similar drugs?
0 of 4 similar drugs in Non-Alcoholic Steatohepatitis (NASH) were approved
Approved (0) Terminated (0) Active (4)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02466516 | Phase 2 | Completed |
Competing Products
20 competing products in Non-Alcoholic Steatohepatitis (NASH)